Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Campenni

Urology Pittston, PA Doctor of Osteopathy

NPI 1053313478 CMS profile 320008

250 Kennedy Blvd Unit 2, Pittston, PA 18640

Open in the dashboard

General payments

$6,420

285 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Campenni of Pittston, PA is reported in the CMS Open Payments database as having received $6,420 across 285 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $811 35
2024 General $310 18
2023 General $471 24
2022 General $1,046 38
2021 General $1,172 53
2020 General $1,088 52
2019 General $1,521 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Campenni
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Michael Campenni were reported at $811. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Michael Campenni Urology median Middle half National median
2019 $1,521 $480 $147–$1,201 $163
2020 $1,088 $246 $87–$645 $114
2021 $1,172 $358 $111–$1,000 $132
2022 $1,046 $476 $143–$1,263 $149
2023 $471 $560 $168–$1,461 $160
2024 $310 $563 $170–$1,464 $164
2025 $811 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $1,464 55 payments
  2. Astellas Pharma US Inc $1,206 51 payments
  3. Pfizer Inc. $1,104 57 payments
  4. AbbVie, Inc. $453 16 payments
  5. Teleflex LLC $361 15 payments
  6. Sumitomo Pharma America, Inc. $242 18 payments
  7. Medtronic, Inc. $238 16 payments
  8. Dentsply Ih AB $173 5 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $125 1 payment
  10. Novo Nordisk Inc $116 1 payment
  11. Other $937 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,194 282 payments
  2. Education $226 3 payments
Products named General payments · program years 2019–2025
  1. XTANDI $1,431 70 payments
  2. Nubeqa $1,210 50 payments
  3. Xofigo $625 27 payments
  4. MYRBETRIQ $488 32 payments
  5. LUPRON DEPOT $269 12 payments
  6. GEMTESA $242 18 payments
  7. ORGOVYX $220 17 payments
  8. INTERSTIM $212 15 payments
  9. UroLift System $204 7 payments
  10. LoFric $173 5 payments
  11. Other $1,788 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,757

Median for Urology: 1,053

Drug cost

$121,412

Median for Urology: $101,464

Branded share of claims

39.2%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 63 $57,330
Gemtesa Vibegron Brand 28 $21,581
Alfuzosin Hcl Er Alfuzosin Hcl Brand 390 $11,802
Tamsulosin Hcl Generic 286 $7,006
Dutasteride Generic 134 $5,841
Solifenacin Succinate Generic 164 $4,853
Finasteride Generic 193 $3,979
Oxybutynin Chloride Er Oxybutynin Chloride Brand 79 $2,130
Doxazosin Mesylate Generic 63 $1,357
Tadalafil Generic 12 $1,276

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$152,668

Of which drugs: $17,311

Medicare patients

680

Average age 75

Services billed

1,993

161 women, 519 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 36%
Diabetes 32%
Chronic kidney disease 27%
Cancer 26%
Atrial fibrillation 22%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 14 121 $16,811
Injection, ceftriaxone sodium, per 250 mg J0696 Office 28 112 $39

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Nubeqa
  • Bayer HealthCare Pharmaceuticals Inc. $101
$101 — —
Xofigo
  • Bayer HealthCare Pharmaceuticals Inc. $36
$36 — —
LUPRON DEPOT
  • AbbVie, Inc. $28
$28 — 121
Veozah
  • Astellas Pharma US Inc $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record